...
首页> 外文期刊>Clinical immunology: The official journal of the Clinical Immunology Society >CXCR6 gene characterization in two ethnically distinct South African populations and association with viraemic disease control in HIV-1-infected black South African individuals
【24h】

CXCR6 gene characterization in two ethnically distinct South African populations and association with viraemic disease control in HIV-1-infected black South African individuals

机译:在艾滋病毒-1感染黑色南非个体中,两个种族不同的南非群体和疾病疾病控制联系的CXCR6基因特征

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

CXCR6 genetic variation was described for HIV-1-uninfected black (n = 41) and Caucasian (n = 40) South Africans. We also investigated the CXCR6 rs2234358 and rs2234355 single nucleotide polymorphisms in HIV-1 disease control in 124 HIV-1-infecteddrug-na ve black individuals [elite controllers (n = 11), viraemic controllers (VCs, n = 30), high viral load long-term nonprogressors (HVL LTNPs, n = 11) and progressors (n = 72)] compared to healthy controls (HCs; n = 232). The rs2234358-T allele was underrepresented in VCs (40.0%) compared to HCs (59%, P = 0.006), HVL LTNPs (72.7%, P = 0.012) and progressors (59%, P = 0.014). The rs2234358TT genotype was underrepresented in VCs (7%) compared to progressors (32%; OR = 6.57, P = 0.006) and HCs (35%; OR = 7.18, P = 0.001, P-bonferroni = 0.034). The rs2234355-GA genotype was overrepresented in VCs (80%) compared to HCs (50.4%; OR = 025,P= 0.003) and progressors (29.17%; OR = 0.10,P = 3.8 x 10(-5,) P-bonferroni = 0.001). The combination of rs2234355-GA in the absence of rs2234358-TT was overrepresented in VCs (80%) compared to HCs (32.6%, OR = 0.12, P = 1 x 10(-6), P-bonferroni = 3.4 x 10(-5)) and to progressors (16.7%; OR = 0.05, P< 1 X 10(-8), P-bonferroni <1 X 10(-7)). (C) 2017 Elsevier Inc. All rights reserved.
机译:CXCR6遗传变异描述于HIV-1 - 未感染的黑色(n = 41)和白种人(n = 40)南非人。我们还在124个HIV-1-感染液-Na VE黑色个体中调查了CXCR6 RS2234358和RS2234355的单核苷酸多态性[ELITE控制器(N = 11),病毒控制器(VCS,N = 30),高病毒与健康对照(HCS; N = 232)相比,负载长期非竞争器(HVL LTNP,N = 11)和进展(n = 72)]。与HCs(59%,P = 0.006),HVL LTNP(72.7%,P = 0.012)和进展(59%,P = 0.014)相比,RS2234358-T等位基因在VCS(40.0%)中受到了众所谓(40.0%)。与进展者相比,RS2234358TT基因型在VCS(7%)中(32%;或= 6.57,P = 0.006)和HCS(35%;或= 7.18,P = 0.001,P-Bonferroni = 0.034)。与HCs(50.4%;或= 025,P = 0.003)和进步相比,RS2234355-GA基因型超过VCS(80%)(80%)(29.17%;或= 0.10,P = 3.8 x 10(-5)p- Bonferroni = 0.001)。与HCS相比,在没有RS2234358-TT的情况下,在没有RS2234358-TT的情况下,RS2234355-GA的组合在VCS(80%)中(32.6%,或= 0.12,P = 1×10(-6),P-Bonferroni = 3.4×10( -5))和进步(16.7%;或= 0.05,P <1×10(-8),P-Bonferroni <1×10(-7))。 (c)2017年Elsevier Inc.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号